Sanofi S.A.
Develops and markets pharmaceutical therapies across immunology, rare diseases, oncology, and vaccines including paediatric, respiratory, and combination formulations.
As of Jul 17, 2026
Executive summary
Sanofi is a major European pharmaceutical and healthcare company traded on Euronext Paris with a market capitalisation of €92.1 billion. The stock is trading at €76.94 and shows a bullish technical bias, having gained 2.8% over the past month, though it remains down 1.3% year-on-year.
Price history
As of Jul 16, 2026
Performance
+0.89%
+0.60%
+2.75%
-0.95%
-1.79%
-1.29%
As of Jul 16, 2026
Technical indicators
- 56
- 0.22Bullish
- 50: 75.23 · 200: 77.18
- €72.93 / €77.49
Technical Bias
Bullish lean
The technical setup for Sanofi S.A. presents a mixed but slightly favourable lean. MACD momentum is positive at 0.22, whilst RSI sits neutrally at 56 and the moving averages offer no directional tilt, leaving a tally of one bullish, two neutral signals. This is a derived technical read, not a recommendation, and price currently trades near resistance at €77.49 with support nearby at €72.93.
A transparent read of the indicators below — not a prediction or recommendation.
As of Jul 16, 2026
Fundamentals
- €92.1B
- 19.43
- €3.96
- 15.95%
- +6.0%
- €8.99B
- 0.28
- €70.89 – €86.32
- 5.40%
- May 5, 2026
- Jul 30, 2026 (12 days)
As of Jul 17, 2026
Upcoming catalysts
- Earnings report
As of Jul 17, 2026
Latest news
As of Jul 17, 2026
Short-term outlook
Sanofi shares have edged up 2.8% over the past month, and MACD is giving a bullish signal even as RSI sits at a neutral 56. With the 50-day and 200-day averages bunched around €75-77, the stock looks caught between €72.93 support and €77.49 resistance, and a break either way could set the near-term tone ahead of the next earnings update on July 30, 2026.
Medium-term outlook
Sanofi's fundamentals show steady 6.0% revenue growth alongside a solid 16.0% profit margin, backed by a 5.4% dividend yield that offers a meaningful income cushion. Trading at 19.43 times earnings, the stock isn't cheap but reflects confidence in continued growth. With technicals currently leaning bullish, the next few quarters could see this combination of steady fundamentals and positive price momentum continue to attract attention.
Key risks
- Sanofi trades well off its 52-week high of €86.32, sitting at €76.94, which shows the stock has faced renewed selling pressure.
- Competitor momentum in the cholesterol treatment space, highlighted by Merck's new approval and share gains, points to intensifying competitive pressure across the pharmaceutical sector Sanofi operates in.
- A profit margin of 16.0% alongside revenue growth of 6.0% suggests Sanofi still needs to convert top-line gains into stronger profitability, leaving limited room for cost pressures or pricing setbacks.
- With a beta of just 0.28, Sanofi tends to move independently of broader market swings, meaning its share price is likely more sensitive to company-specific news such as trial results or regulatory decisions than to macro sent
About Sanofi S.A.
Sanofi S.A. is a France-based healthcare group listed on Euronext Paris under the ticker SAN, operating in the drug manufacturers segment of the broader pharmaceutical industry. With a market capitalisation of €92.1 billion, it ranks among the larger players in European healthcare, reflecting its scale in developing and supplying medicines across global markets.
Sanofi's price-to-earnings ratio of 19.43 gives you a sense of how the market values its earnings relative to the wider drug manufacturing sector. The dividend yield of +5.4% points to a notable income component for shareholders, a factor often associated with established pharmaceutical companies that generate steady cash flow. Together, these figures offer a snapshot of how investors currently price Sanofi's earnings and shareholder returns within the healthcare space.
AI-assisted research for informational purposes only — not investment advice. Figures are sourced from third-party market data and may be delayed. Do your own research before trading. Your capital is at risk.